30.88
price down icon0.19%   -0.06
 
loading
Schlusskurs vom Vortag:
$30.94
Offen:
$31.26
24-Stunden-Volumen:
1.60M
Relative Volume:
0.71
Marktkapitalisierung:
$4.54B
Einnahmen:
$264.79M
Nettoeinkommen (Verlust:
$-14.36M
KGV:
-280.73
EPS:
-0.11
Netto-Cashflow:
$-28.11M
1W Leistung:
+0.55%
1M Leistung:
+3.42%
6M Leistung:
+23.18%
1J Leistung:
+137.17%
1-Tages-Spanne:
Value
$30.37
$31.50
1-Wochen-Bereich:
Value
$29.73
$31.57
52-Wochen-Spanne:
Value
$12.90
$36.84

Tg Therapeutics Inc Stock (TGTX) Company Profile

Name
Firmenname
Tg Therapeutics Inc
Name
Telefon
(212) 554-4484
Name
Adresse
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Name
Mitarbeiter
0
Name
Twitter
@TGTherapeutics
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
TGTX's Discussions on Twitter

Vergleichen Sie TGTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TGTX
Tg Therapeutics Inc
30.88 4.54B 264.79M -14.36M -28.11M -0.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.24 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
700.33 76.56B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
644.48 39.16B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
250.59 32.44B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
120.01 28.77B 3.30B -501.07M 1.03B -2.1146

Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-10-29 Eingeleitet TD Cowen Buy
2023-08-02 Hochstufung Goldman Sell → Neutral
2023-06-26 Fortgesetzt Jefferies Buy
2022-05-20 Eingeleitet BofA Securities Underperform
2022-02-23 Bestätigt B. Riley Securities Buy
2021-11-15 Herabstufung Goldman Neutral → Sell
2021-04-20 Eingeleitet Goldman Neutral
2021-04-19 Bestätigt H.C. Wainwright Buy
2020-09-01 Eingeleitet JP Morgan Overweight
2020-08-11 Bestätigt H.C. Wainwright Buy
2020-06-05 Eingeleitet Evercore ISI Outperform
2020-01-17 Bestätigt H.C. Wainwright Buy
2019-11-27 Fortgesetzt B. Riley FBR Buy
2019-02-06 Fortgesetzt Jefferies Buy
2018-09-25 Herabstufung Raymond James Strong Buy → Outperform
2018-03-09 Bestätigt B. Riley FBR, Inc. Buy
2017-12-01 Fortgesetzt B. Riley FBR, Inc. Buy
2017-11-14 Fortgesetzt H.C. Wainwright Buy
2017-04-25 Eingeleitet Jefferies Buy
2017-03-06 Bestätigt FBR & Co. Outperform
2016-10-06 Fortgesetzt Brean Capital Buy
2016-05-27 Eingeleitet SunTrust Buy
2015-12-01 Eingeleitet FBR Capital Outperform
2015-09-09 Eingeleitet Raymond James Strong Buy
2015-08-12 Fortgesetzt H.C. Wainwright Buy
2015-06-19 Bestätigt Brean Capital Buy
2014-12-11 Bestätigt ROTH Capital Buy
2014-12-10 Bestätigt ROTH Capital Buy
Alle ansehen

Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten

pulisher
Feb 18, 2025

TG Therapeutics Announces Schedule of Data Presentations - GlobeNewswire

Feb 18, 2025
pulisher
Feb 18, 2025

Groundbreaking BRIUMVI MS Treatment Data: 4 Critical Studies Reveal Real-World Impact at ACTRIMS - StockTitan

Feb 18, 2025
pulisher
Feb 14, 2025

TG Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Feb 14, 2025
pulisher
Feb 14, 2025

TG Therapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 16, 2022 to Discuss Your RightsTGTX - Newsfile

Feb 14, 2025
pulisher
Feb 14, 2025

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Entropy Technologies LP - MarketBeat

Feb 14, 2025
pulisher
Feb 13, 2025

Bleakley Financial Group LLC Purchases Shares of 8,140 TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Feb 13, 2025
pulisher
Feb 13, 2025

TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of autoimmune diseases - MSN

Feb 13, 2025
pulisher
Feb 12, 2025

TG Therapeutics Licenses Maxcyte Tech to Develop Cell Therapies for Autoimmune Disease - Genetic Engineering & Biotechnology News

Feb 12, 2025
pulisher
Feb 12, 2025

46,655 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Bought by Strategic Financial Concepts LLC - MarketBeat

Feb 12, 2025
pulisher
Feb 12, 2025

How Small, But 'Mighty' TG Therapeutics Scored A 470% Gain Over 13 Months - Yahoo

Feb 12, 2025
pulisher
Feb 12, 2025

MaxCyte Signs Licensing Deal With TG Therapeutics For Next-Gen Autoimmune Cell Therapies - Nasdaq

Feb 12, 2025
pulisher
Feb 12, 2025

MaxCyte signs SPL deal with TG Therapeutics - ShareCast

Feb 12, 2025
pulisher
Feb 12, 2025

MaxCyte Signs Platform License Deal With TG Therapeutics -February 12, 2025 at 05:07 am EST - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

MaxCyte, TG Therapeutics sign strategic platform license to advance autoimmune cell therapeutics programs - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

MaxCyte Licenses Cell-Engineering Technology to TG Therapeutics -February 12, 2025 at 04:37 am EST - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

Major Autoimmune Breakthrough: MaxCyte Technology Powers Next-Gen Multiple Sclerosis Treatment - StockTitan

Feb 12, 2025
pulisher
Feb 12, 2025

MaxCyte Partners with TG Therapeutics for Autoimmune Cell Therapy - TipRanks

Feb 12, 2025
pulisher
Feb 12, 2025

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - The Manila Times

Feb 12, 2025
pulisher
Feb 12, 2025

Maxcyte Says Enters Strategic Platform License With TG Therapeutics -February 12, 2025 at 02:18 am EST - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

MaxCyte Enters Strategic License Agreement with TG Therapeutics for Cell-Based Therapy Development - Nasdaq

Feb 12, 2025
pulisher
Feb 12, 2025

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell ... - The Bakersfield Californian

Feb 12, 2025
pulisher
Feb 10, 2025

SG Americas Securities LLC Has $233,000 Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Feb 10, 2025
pulisher
Feb 10, 2025

Stratos Wealth Advisors LLC Acquires New Stake in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Feb 10, 2025
pulisher
Feb 08, 2025

Institutional investors are TG Therapeutics, Inc.'s (NASDAQ:TGTX) biggest bettors and were rewarded after last week's US$199m market cap gain - Simply Wall St

Feb 08, 2025
pulisher
Feb 08, 2025

TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Feb 08, 2025
pulisher
Feb 06, 2025

TGTX March 28th Options Begin Trading - Nasdaq

Feb 06, 2025
pulisher
Feb 06, 2025

Symphony Financial Ltd. Co. Acquires New Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Feb 06, 2025
pulisher
Feb 05, 2025

Precision Wealth Strategies LLC Makes New $530,000 Investment in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Feb 05, 2025
pulisher
Feb 04, 2025

TG Therapeutics (NASDAQ:TGTX) Rating Lowered to "Sell" at StockNews.com - MarketBeat

Feb 04, 2025
pulisher
Jan 30, 2025

Nisa Investment Advisors LLC Buys 2,803 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World

Jan 30, 2025
pulisher
Jan 28, 2025

Trading (TGTX) With Integrated Risk Controls - Stock Traders Daily

Jan 28, 2025
pulisher
Jan 28, 2025

All You Need to Know About TG Therapeutics (TGTX) Rating Upgrade to Buy - MSN

Jan 28, 2025
pulisher
Jan 25, 2025

TG Therapeutics (NASDAQ:TGTX) Stock Price Up 6.8%Here's What Happened - MarketBeat

Jan 25, 2025
pulisher
Jan 25, 2025

Why TGTX Stock Is Rallying Today - MSN

Jan 25, 2025
pulisher
Jan 23, 2025

TG Therapeutics: Entering 2025 With Increased Investor Expectations (NASDAQ:TGTX) - Seeking Alpha

Jan 23, 2025
pulisher
Jan 23, 2025

Cantor Fitzgerald Weighs in on TG Therapeutics FY2025 Earnings - Defense World

Jan 23, 2025
pulisher
Jan 22, 2025

Assenagon Asset Management S.A. Decreases Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Jan 22, 2025
pulisher
Jan 21, 2025

TG Therapeutics: 2025 Revenues Will Smash Expectations (NASDAQ:TGTX) - Seeking Alpha

Jan 21, 2025
pulisher
Jan 20, 2025

12 Hot Stocks to Buy According to Analysts - Insider Monkey

Jan 20, 2025
pulisher
Jan 20, 2025

Here’s Why Analysts Are Bullish on TG Therapeutics, Inc. (TGTX) - Insider Monkey

Jan 20, 2025
pulisher
Jan 18, 2025

TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last? - MSN

Jan 18, 2025
pulisher
Jan 18, 2025

(TGTX) Trading Signals - Stock Traders Daily

Jan 18, 2025
pulisher
Jan 18, 2025

Brookstone Capital Management Acquires 624 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World

Jan 18, 2025
pulisher
Jan 18, 2025

FY2024 EPS Forecast for TG Therapeutics Increased by Analyst - Defense World

Jan 18, 2025
pulisher
Jan 17, 2025

Is TG Therapeutics Inc. (TGTX) Among Tuesday’s Top Gainers? - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

TG Therapeutics FY2024 EPS Forecast Raised by HC Wainwright - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

TG Therapeutics Provides Preliminary Fourth Quarter and Full-Year Financial Results in SEC Filing - Defense World

Jan 17, 2025
pulisher
Jan 16, 2025

TG Therapeutics: Cash Positive But Playing Defense (Rating Downgrade) (NASDAQ:TGTX) - Seeking Alpha

Jan 16, 2025
pulisher
Jan 16, 2025

TG Therapeutics FY2025 EPS Forecast Raised by HC Wainwright - MarketBeat

Jan 16, 2025
pulisher
Jan 15, 2025

TG Therapeutics' (TGTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Jan 15, 2025
pulisher
Jan 15, 2025

TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise - MSN

Jan 15, 2025

Finanzdaten der Tg Therapeutics Inc-Aktie (TGTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Tg Therapeutics Inc-Aktie (TGTX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Power Sean A
CFO
Jan 06 '25
Sale
28.53
10,021
285,939
660,611
$33.42
price up icon 0.27%
$81.06
price down icon 3.05%
$361.10
price down icon 1.70%
$22.12
price down icon 4.08%
biotechnology ONC
$255.37
price up icon 4.57%
$120.01
price up icon 1.81%
Kapitalisierung:     |  Volumen (24h):